Vázquez-Bourgon J, et al. - Researchers examined a sample of first-episode (FEP) non-affective psychosis to explore the influence of cannabis consumption on hepatic steatosis. They evaluated 390 patients at baseline and 3 years following initiation of the antipsychotic treatment. At the 3-year follow-up, significantly lower Fatty Liver Index (FLI) scores were evident in cannabis users vs non-users (F = 13.874). In addition, cannabis users vs non-users less frequently met the criteria for liver steatosis. Longitudinally, they noted the smallest increment in FLI over time in patients maintaining cannabis consumption over 3 years; this increment was significantly smaller than the FLI increment presented by discontinuers and never-users. Findings thereby suggest that a protective effect is produced by cannabis consumption against liver steatosis in psychosis; the modulation of antipsychotic-induced weight gain may be related to this protective effect.